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The National Institute of Health has estimated that over 1 million new cancer cases will 
occur yearly. Posttraumatic stress disorder (PTSD) is commonly associated with near 
death experiences or traumatic events, such as cancer diagnosis and treatment. There is a 
lack of knowledge and awareness by healthcare professionals in identifying PTSD in 
cancer patients. In this population, PTSD symptoms often contribute to anxiety, and there 
is no standardized protocol being used to screen these individuals for the trauma they are 
facing or have faced. The purpose of this project was to develop a clinical practice 
guideline for screening cancer patients for PTSD in a clinic population serving 20% 
cancer patients. The stress theory developed by Lazarus and Folkman guided this project. 
The project questions were to identify the most appropriate screening tool for PTSD in 
cancer patients and recommend a clinical practice guideline to the clinic healthcare 
providers. Five widely used PTSD screening tools were reviewed. Based on the project 
question the Clinician Administered PTSD Scale was identified as the most appropriate 
for this clinic setting and patient population. An expert panel consisting of 3 experienced 
psychiatric nurse practitioners reviewed the proposed guideline using the AGREE II tool. 
Using a scale of 1 (strongly disagree) to 7 (strongly agree), the team members agreed 
with a score of 5 or higher in each domain with the proposed guideline. Utilization of this 
guideline will promote a positive social change towards mental health awareness and 
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Section 1: Nature of the Project 
Introduction 
Cancer is the name given to a collection of related diseases in the body in which a 
person’s own cells begin to divide without stopping and spread into surrounding tissues 
(National Institute of Health [NIH], 2019). About 1.2 million new cancer cases are 
diagnosed annually in the United States (National Cancer Institute, 2019). Cancer-related 
posttraumatic stress syndrome (PTSD) has been documented in patients with cancer. 
PTSD is characterized by the inability to relax for fear that a trauma will return as well as 
the avoidance of triggers associated with the trauma, such as certain part of town or a 
certain smell. PTSD can also include reliving a traumatic event in nightmares and/or 
flashbacks (NIH, 2019).  
PTSD is positively associated with other indices of distress and reduced quality of 
life and is often associated with risk factors such as prior trauma history, preexisting 
psychiatric conditions, or poor social skills (Cardova et al., 2017). The DSM-5 has 
included cancer-related stress as an implication for PTSD criteria (American 
Psychological Association, 2013). Research by the American Cancer Society (2019) 
supports psychosocial assessments on all cancer patients. Treatment of cancer-related 
PTSD should be approached with caution and be informed by existing evidence-based 
approaches for traumatic stress (CITE). Many patients are not referred for counseling or 
do not accept referrals to psychology-oncology services to be assessed and treated 
because high levels of sadness and anxiety are often perceived as “normal” reactions to 
cancer diagnosis and treatment; therefore, mood, anxiety, and other psychological 
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disorders are commonly mistaken for unexpected, “manageable” sadness and 
preoccupation with the disease (Grassi, Spiegel, & Riba, 2017). Emotional instability can 
cause these patients to question their spirituality, personal values, and existence as well as 
put strains on their personal relationships (CITE).  
Mental health complications can occur at time of diagnosis, during and after 
cancer treatments, and at survivorship. The NIH (2019) reported that PTSD symptoms 
vary for each patient; however, symptoms will typically develop within 3 months of a 
traumatic event up to several months or even years later. Side effects of cancer and 
treatments can significantly influence a patient’s psychological state, potentially causing 
a patient to be more susceptible to developing PTSD during a traumatic event in the 
diagnosis, treatment, or survivorship (Caruso et al., 2017). Kirch (2019), director of 
quality of life and survivorship at the American Cancer Society, reported that screening 
for PTSD helps cancer centers identify patients early on who may be particularly 
vulnerable to lasting mental scars.  
We just don’t do a good job in general in oncology for screening for PTSD or 
even assessing anxiety and depression. Oncologists might have a hard time 
figuring this out because they treat a lot of people, and many don’t report 
psychiatric symptoms and screening needs to be one of the first steps. (Ganz, 
2019, p. 5).  
The accuracy of diagnosis requires the use of reliable and valid instruments. The 
development of a clinical practice guideline (CPG) at the project facility that screens for 
PTSD will help facilitate an appropriate treatment plan for these individuals, promoting 
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optimal patient care. The purpose of this project was to provide healthcare providers with 
a CPG that promotes the use of a reliable and valid PTSD screening tool for patients in a 
variety of cancer situations.  
Problem Statement 
The setting of this Doctor of Nursing Practice (DNP) project was a private, 
psychiatric clinic in the north central United States. This clinic provides psychological 
and psychiatric services to both children and adults. This facility was an appropriate 
setting for this project because it receives referrals for this population from primary care 
and oncology providers. Estimates from the facility administration are that 1 out of 5 (or 
20%) of patients at this clinic currently have or have been diagnosed with cancer at some 
point in their life. This community has a large influx of cancer patients because it is 
centrally located and has an oncology center. Healthcare providers at this facility are 
expected to screen and manage patients with mental illness using the best evidence-based 
practices. This facility screens cancer patients for depression with use of the PHQ9 at 
every visit. The generalized anxiety tool, known as the GAD7, which screens for the four 
most common anxiety disorders, is utilized when a cancer patient presents to the clinic 
with a chief complaint of daily anxiety, panic episodes, and obsessive behaviors and/or 
thoughts.  
Common symptoms of PTSD that a cancer patient may exhibit when they are 
unable to deal with trauma of having cancer include reminiscing about traumatic 
experiences over and over, intrusive thoughts, avoiding anything that could remind them 
of the traumatic event, difficulties with the control of their emotions, panic, intense 
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fear/anxiety, nightmares, and an overall difficulty with sleep (CITE). The earlier PTSD is 
diagnosed, the more successful treatment can be (CITE). If PTSD is left untreated for 
long periods of time, certain symptoms can be exacerbated, and many areas of a patient’s 
life are severely affected (NIH, 2019). This doctoral project holds significance for social 
change by providing education, advances in nursing, and the practice goal of improving 
patient outcomes and promoting positive social change.  
Purpose Statement 
Lack of knowledge and awareness by health professionals contributes to the 
underdiagnosis of PTSD in cancer patients. Identification of cancer status and screening 
for PTSD at the initial psychiatric evaluation and subsequence visits is a proactive 
approach to ensure that this problem is addressed in this population. Chan et al. (2017) 
conducted a research study that involved 469 cancer patients who had been diagnosed 
with various types of cancer. All patients for their study were recruited within 1 month of 
their diagnosis at the same oncology referral clinic. The participants in their study were 
evaluated for PTSD symptoms first after 6 months following their cancer diagnosis, then 
again after 4 years. Chan et al. discovered that nearly one fifth of the participants 
experienced PTSD symptoms within a few months of their cancer diagnosis, and many of 
these people continued to display PTSD symptoms 4 years after their diagnosis.  
Healthcare providers caring for cancer patients must understand and detect PTSD 
symptoms in their patients to provide optimal care. The project questions were:  
1. Based on the current evidence, what is the most appropriate screening tool for 
PTSD in cancer patients?   
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2. Based on the evidence reviewed, what CPG recommendations should be made 
to the clinic healthcare providers?  
Providing a CPG to healthcare providers for cancer patients suffering from PTSD will 
increase their confidence when caring for patients in this population. Early screening and 
detection can help promote various treatments used in treated PTSD, ultimately 
improving this population’s quality of life.  
Nature of the Doctoral Project 
For this project, I reviewed evidence accessed through the Walden University 
Library, including from the CINAHL, Medline, ProQuest, Psych Info, PubMed, and 
Google Scholar databases. Inclusion criteria included English language only peer-
reviewed resources published within the past 5 years. CPGs related to the topic were also 
reviewed. Keyword search terms included PTSD, cancer and PTSD, psychological 
impact of cancer, cancer, and cancer screenings for mental health. In this project, I 
followed the guidelines set forth in the Walden University DNP Manual for Clinical 
Practice Guideline Development. CPG development requires a systematic method with 
inclusion and exclusion criteria to search the literature and grade the strength of evidence 
(Moran, Burson, & Conrad, 2017). The Appraisal of Guidelines Research and Evaluation 
(AGREE) II instrument provided the framework for the development of this guideline. 
The AGREE II is both valid and reliable and consists of 23 key items organized within 






The primary stakeholders for this doctoral project were the nursing staff and 
clinicians at this practicum site. Other stakeholders included family members, 
oncologists, and primary care clinicians. Early identification and management of PTSD 
will reduce the burden on insurance companies and third-party payers. This guideline will 
encourage early screening and interventions in this population in efforts to reduce costs 
of mental health and medical care across the lifespan (see Bellmore, 2016). The 
contributions of this doctoral project include recommendations from the review and 
initiation of a CPG that allows for nurses and clinicians to identify, screen, and treat for 
PTSD in this population. Ultimately, this guideline will promote social change by 
improving the patient’s quality of life, family structure, and relationships as well as 
promote mental health awareness for communities, patients, nursing staff, and clinicians. 
“Mental illness-related stigma, including that which exists in the healthcare system and 
among healthcare providers, creates serious barriers to access and quality care” (Knaak, 
Mantler, & Szeto, 2017, p. 111). 
I integrated scholarship into this project by conducting a thorough literature 
review in order to evaluate and apply up-to-date evidence focusing on the improvement 
of patient outcomes. The role of the DNP in scholarship, in relation to Essential III: 
Clinical Scholarship and Analytical Methods for Evidence-Based Practice, includes 
discovering and integrating knowledge through the examination and synthesis of 
academic literature, integrating knowledge from other disciplines by giving meaning to 
isolated facts, and applying new knowledge in the practice setting (American Association 
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of Colleges of Nursing [AACN], 2006). The project also aligned with DNP Essential VI: 
Clinical Prevention and Population Health for Improving the Nation’s Health, which 
incorporates leadership from the DNP-prepared clinician to integrate evidence-based 
clinical prevention and population health services for individuals, such as those suffering 
from the psychological aspects of cancer (AACN, 2006).  
Walden University’s (2019) School of Nursing provided a rigorous and culturally 
relevant approach to educational programs, based on a scholar-practitioner model. This 
project influenced social change by supplying clinicians with evidence that will help 
them with the early identification of mental illness in cancer patients with the goal of 
enhancing the quality of life for their patients and families. The recommendations from 
this project supported providers with identifying, screening, and treating PTSD in this 
population.  
Summary 
In Section 1, I introduced the current gap in knowledge regarding which screening 
tools are the most effective for the early identification of mental illness amongst cancer 
patients. The nature of the project and the importance to stakeholders were explored. The 
significance of developing this CPG to nursing practice was also described. In Section 2, 
I provide an in-depth discussion of the background and context of the doctoral project as 




Section 2: Background and Context 
Introduction 
The current screening procedure at a private psychiatric clinic in the north central 
United States was to screen all cancer patients for depression with the PHQ9 tool as well 
as the GAD7 when anxiety symptoms were of concern. Currently, cancer patients are not 
screened for PTSD even though current literature indicates that PTSD in this population 
is extremely prevalent. The project questions were:  
1. Based on the current evidence, what is the most appropriate screening tool for 
PTSD in cancer patients?   
2. Based on the evidence reviewed, what CPG recommendations should be made 
to the clinic healthcare providers?  
In this section, I explored the concepts and model that framed the project. The 
relevance to nursing practice are synthesized. I also described the local background and 
context for the project and discussed my role in developing and presenting the CPG to 
stakeholders. 
Concepts, Models, and Theories 
In this project, I used the stress theory, developed by Lazarus and Folkman, for 
the development of this CPG. The framework of the stress theory integrates stress, 
appraisal, and coping as they relate to how individuals react to psychologically stressful 
situations and/or environments (CITE). This clinical assessment of an individual’s coping 
reaction facilitates enhanced clinical decision-making on how best to intervene as well as 
provide one possible clinical indication of who will engage in maladaptive or adaptive 
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coping (Folkman & Moskowitz, 2000). In clinical practice, this theoretical framework 
has been utilized in the assessment, intervention, and evaluation of an individual’s 
psychological stress and coping responses (CITE). Stress theories provide nursing with a 
framework through which to understand the effects that stress has on individual and how 
the individual responds to stressful situations and life events (McEwen & Will, 2011).  
For this project, the theory of stress, coping, and adaptation, created by Lazarus 
and Folkman (1984), was used to help healthcare providers understand the effects of 
stress and how a person responds to stress. Kato (2014) indicated the importance for 
healthcare providers to understand the role of coping for optimal healthcare provider and 
patient communication, interactions, and the ability to help patients learn and adapt to 
their traumatic events. Lazarus (1984) stated that cognitive appraisal occurred when a 
person considers two major factors that contribute to their response to stress: (a) the 
threatening tendency of the stress to the individual and the assessment of resources 




. In general, cognitive appraisal is divided into two types or stages: primary and 
secondary appraisal (Kato, 2014). 
 
Figure 1. Lazarus and Folkman’s theory of stress and coping.  
Lazarus (1984) provided the following definitions for terms important for 
understanding the theory of stress and coping: 
• Stress: The physiological response to threatening or challenging events in the 
environment. 
• Coping: The process of spending conscious effort and energy to solve 
personal and interpersonal problems. 
• Adaption: The change that takes place as a result of the response to a stressor. 
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CPG development requires a systematic method with inclusion and exclusion 
criteria to search the literature and grade the strength of evidence (Moran et al., 2017). 
The AGREE II tool provided the framework for the development of this guideline.  
Relevance to Nursing Practice 
The development of an evidenced-based CPG that addresses PTSD in cancer 
patients in a psychiatric care setting advances the field of nursing practice because it 
addresses a clinical problem using current evidence and increases healthcare providers’ 
confidence when caring for patients in this population. Early screening and detection can 
help promote varied treatments for PTSD, ultimately improving this population’s quality 
of life. The lack of knowledge and awareness of healthcare professionals contributes to 
the underdiagnosis of PTSD in cancer patients (Knaap et al., 2014). In the following 
subsections, I review existing research on this practice problem.  
PTSD 
About 70% of people worldwide will experience a traumatic event; yet, the 
lifetime prevalence of PTSD is only at 5% (Atwoli et al., 2015). Other researchers have 
shown that 4%–55% of this population should have a cancer-related PTSD diagnosis 
(Cordova, Riba, & Spiegal, 2017). Chan et al. (2018) reported a strong prevalence of 
PTSD in cancer patients at both 6 months and 4 years following cancer diagnosis. Chan 
et al. also reported that the overall rate of PTSD decreased with time from 21.7% 
incidence at 6 months to 6.1% incidence at 4 years. Over one third of participants who 
were initially diagnosed with PTSD had persisting or worsening PTSD symptoms within 
4 years of cancer treatments (Chan et al., 2018). The greater social awareness and 
understanding along with reduced mental health stigma associated with cancer will act as 
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a protective factor against PTSD, with this effect lessening as the patient has more years 
in treatment and follow up (Chan et al., 2018).  
PTSD affects all aspects of a patient’s life, including self-image, relationships 
with family and friends, spirituality, ability to work, etc. (Gold et al., 2012). Emotional 
instability can cause patients to question their spirituality, personal values, and the 
meaning of their existence, which can strain patient relationships with loved ones (Grassi 
et al., 2017). Multiple studies have revealed that psychological distress, including cancer-
related PTSD, negatively impact patients’ health, treatment, and quality of life (CITE). 
Because of these factors, it is important for healthcare providers to recognize the signs 
and symptoms of PTSD in this population, including avoidant behaviors that may exhibit 
themselves as missed appointments, failing to complete treatment, or withdrawing from 
friends to avoid speaking about the cancer. Increased psychological distress is further 
correlated with decreased radiation treatment compliance and overall survival (Chen et 
al., 2017). 
PTSD and Cancer Patients 
 
Abbey et al. (2017) indicated an increase in the prevalence rates of cancer-related 
PTSD and that prevalence rates seemed to vary widely based on the method of 
assessment. This study revealed that self-report PTSD symptom measures yielded 
prevalence estimates of clinically significant symptom levels ranging from 7.3% to 
13.8%, depending on screening scoring method used. Investigations using more stringent, 
clinician-administered structured diagnostic interviews for PTSD yielded a lifetime 
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prevalence estimate of 12.6% and a current prevalence estimate of 6.4% (Abbey et al., 
2017).  
In a nationwide cohort study that included all Danish-born residents of Denmark 
from 1995–2011, Gradus et al. reported that 
 Standardized incidence ratios (SIR) were calculated, null associations were found 
between PTSD and nearly all cancer diagnoses examined, both overall (SIR for 
all cancers = 1.0, 95% confidence interval (CI) = 0.88, 1.2) and in analyses 
stratified by gender, age, substance abuse history and time since PTSD diagnosis. 
(p. 568) 
Although research has shown that cancer-related PTSD often has a chronic 
course, researchers have also demonstrated that mental health services are grossly 
underutilized by this population (Kadan-Lottick et al., 2015). Vachon (2006) stated that 
only 10% of cancer patients reporting levels of distress received any type of psychosocial 
therapy. Kadan-Lottick et al. (2015) interviewed 251 patients with advanced cancer and 
found that 55% of those with a major psychiatric disorder did not receive a psychiatric 
referral; yet, 90% of all participants said they would seek psychiatric help if they were 
aware they had an emotional problem.  
Screening Tools for PTSD 
 
The mental health screening tool that formed the basis of the CPG developed in 
this DNP project was the patient questionnaire instrument used for screening of PTSD. 
Selecting a screening tool and establishing a screening process are essential first steps, 
but they are only the beginning of developing a distress-screening program (Kendall et 
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al., 2012). Many positive screens will require an assessment by the appropriate 
psychosocial professional to determine the frequency, intensity, duration, and functional 
impact of the distress (CITE). The assessment may reveal the need for intervention and/or 
referral, so after intervention, follow up and further evaluation are needed ensure that the 
patient’s distress is minimized or eliminated (Kendall et al., 2012). 
Zebrack et al. (2015) suggested that screening tools for psychosocial distress 
should yield reliable and valid results and recommended that institutions adopt screening 
tools that align with the needs of their patient population. The VA (2019) identified the 
CAPS screening tool as the gold standard in PTSD assessments. Their rationale for this 
statement was that the tool, with its structured interview, provided a categorical diagnosis 
as well as a measure of the severity of PTSD symptoms as defined by DSM-IV. Table 1 





Description Pros  Cons 
PCL-5 20-item self-report measure 
that assesses the 20 DSM-5  
symptoms of PTSD.  
Monitors symptom change 
during and after treatment, 
Screens individuals for 
PTSD, and make a 
provisional PTSD diagnosis 
(VA, 2019) 
 
The PCL-5 is 
part of a national 
effort to establish 
PTSD outcome 
measures. 
It is well validated, 
and much include 
one Checklist for 
DSM-5. (PCL-5) is 
one of the most 
commonly used self-
report measures of 
PTSD (VA, 2019) 
The PCL-5 can be 
completed in five 
to seven minutes. 
  
Self-survey, 
patients may not be 
honest.  
 





PCL-S The PCL-S (specific) asks 
about symptoms in relation 
to an identified "stressful 
experience." The PCL-S 
aims to link symptom 
endorsements to a specified 
event (VA, 2019). 
 
This screening tool 
asks specific 
questions geared to a 
specific traumatic 
event.  
It is only related to 
a specific event.  
 
Patients may not be 
honest.  
PCL-C The PCL-C (civilian) asks 
about symptoms in relation 
to generic “stressful 
experiences” and can be 
used with any population. 
This version simplifies 
assessment based on 
multiple traumas because 
symptom endorsements are 
not attributed to a specific 
event. In many 
circumstances it is advisable 
to also assess traumatic 
event exposure to ensure 
that a respondent has 
experienced at least one 
event that meets DSM-IV 
Criterion A (VA, 2019). 
 
The PCL-C is a 
shortened version 






This tool was 




judgment is needed 
when it is utilized 
while generalizing 
it in other clinical 
settings or with 
military members.  
 
Patients may not be 
honest.  
PC-PTSD The PC-PTSD is a screening 
tool for Posttraumatic Stress 
Disorder. This tool has four 
questions and is designed 
for clinical use. It is not 
designed to give a definitive 
diagnosis of PTSD, rather it 
assesses whether a clinical 
interview should be carried 
out for PTSD, thus further 
screening.  
 
The PC-PTSD is a 4-
item screen that was 
designed for use in 
primary care and 
other medical 
settings and is 
currently used to 
screen for PTSD in 
veterans at the VA. 
The screen includes 
an introductory 
sentence to cue 
respondents to 
The screen does not 




This does not 




The authors suggest 
that in most 
circumstances the 
results of the PC-
PTSD should be 
considered 
"positive" if a 
patient answer "yes" 
to any 3 items. 
Those screening 
positive should then 
be assessed with a 
structured interview 
for PTSD.  
CAPS CAPS ask respondents to 
endorse up to three 
traumatic events to keep in 
mind during the interview.  
 
CAPS-5 requires the 
identification of a single 
index trauma to serve as the 
basis of symptom inquiry. 
 
Symptom severity ratings 
are based on symptom 
frequency and intensity. 
 
CAPS-5 is a 30-item 
questionnaire, 
corresponding to 
the DSM-5 diagnosis 
for PTSD. The 
language of the 
CAPS-5 reflects 
both changes to 
existing symptoms 
and the addition of 
new symptoms 










but no longer 
includes other 
associated symptoms 
(e.g., gaps in 
awareness).  
 
CAPS-5 items are 
rated with a single 
severity score.  
 
Patient not being 
honest, though 
since this is 
administered by a 
trained professional 




Local Background and Context 
The setting of this DNP project was private, psychiatric clinic in north central 
United States. This clinic receives referrals for this population from primary care and 
oncology providers. One out 5 patients at this clinic currently have or have been 
diagnosed with cancer at some point in their life. Healthcare providers at this facility 
currently screen cancer patients for depression with use of the PHQ9 at every visit. The 
generalized anxiety tool known as the GAD-7, which screens for the four most common 
anxiety disorders, was administered when a cancer patient presents to the clinic with a 
chief complaint of daily anxiety, panic episodes, and obsessive behaviors and/or 
thoughts. The use of a CPG at this project site will promote identifying, screening, and 
treating mental illness in this population. Using a CPG will increase the awareness of 
PTSD for their cancer patients, community, nursing staff, and clinicians.  
Role of the DNP Student 
The DNP nurse is often involved in the development of CPGs within a nursing 
specialty (Walden University, 2019). Practice guidelines within a healthcare organization 
or system provide a method to translate evidence into practice and improve outcomes 
(CITE). The assessment of patient needs or scientific advances may generate the 
development of practice guidelines that are informed by a systematic process of review of 
evidence (CITE). In situations where the demand for practice change is quicker than the 
pace of national guideline development, the dissonance may result in a need to develop 
guidelines at the local healthcare organization (White, Dudley-Brown, & Terhaar, 2016). 
The DNP nurse is a future leader of the professional team for evaluation of evidence and 
18 
 
development of a new CPG to meet the needs of this practice site and patients. My role in 
this project was to explore current evidence on PTSD screening tools and develop a CPG 
for recommendation to the facility.  
Summary 
 In Section 2, I discussed the clinical site’s needs and how this project was 
developed to meet them. Lazarus and Folkman’s (1984) stress theory and AGREE II 
were discussed as the methodology and framework used for development of this 
guideline. PTSD screening tools were also identified and evaluated. I identified my role 
in this project as well. In Section 3, I discuss the collection and analysis of the gathered 
evidence and my process for developing the guideline. 
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Section 3: Collection and Analysis of Evidence 
Introduction 
Cancer is the name given to a collection of related diseases in the body in which 
cells begin to divide without stopping and spread into surrounding tissues (NIH, 2019). 
Cancer-related PTSD has been documented in many patients at various stages of cancer 
(Cordova et al., 2017). The current screening procedure at private psychiatric clinic in the 
north central United States was to screen all cancer patients for depression with the PHQ9 
tool. When anxiety symptoms are of concern, the GAD7 tool was also administered. 
Based on my experience at the clinic and reports from other providers, cancer patients 
were not screened for PTSD even though evidence indicated that PTSD in this population 
was extremely prevalent.  
Practice-Focused Questions 
The project questions were:  
1.  Based on the current evidence, what is the most appropriate screening 
tool for PTSD in cancer patients?   
2. Based on the evidence reviewed, what CPG recommendations should be 
made to the clinic healthcare providers?  
Sources of Evidence 
The goal of this project was to review current evidence and guidelines to develop 
a CPG to recommend to a private, psychiatric facility. To complete the literature review 
for this project, I searched for evidence using the following keywords: PTSD, cancer and 
PTSD, psychological impact of cancer, cancer screenings for mental health, and clinical 
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practice guidelines and PTSD. The Walden University Library was accessed to explore 
the following databases: CINAHL, Medline, ProQuest, Psych Info, PubMed, and Google 
Scholar. Inclusion criteria included English language articles that were from peer-
reviewed sources and published within the past 5 years.  
Analysis and Synthesis 
Step 1: Critically Appraise the Evidence 
A critical appraisal of the literature on the topic led to 18 current articles. I 
reviewed each article to determine if it was pertinent to this topic and came from a peer-
reviewed source. My analysis of each article included reviewing the background 
information, study objectives, research method, limitations, conclusions, and references. 
The search results included experimental studies, systematic reviews, peer-reviewed 
articles by content experts, guideline development manuals, and two international CPGs. 
Various authors indicated the need for effective screening and identification of mental 
illness in cancer patients in all situations (CITE). The articles were reviewed using the 
following criteria: 
1. Author, date, and title, 
2. Level of evidence  
3. Analysis, 
4. Conclusions, and 
5. Implications for practice.  
I also reviewed CPGs related to the topic. These guidelines were previously discussed in 
Table 1.  
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Step 2: Synthesize the Evidence from the Literature 




Hierarchy of Evidence Table  
 
Type of Evidence Level of 
Evidence 
Description 
SR or meta-analysis I Synthesis of evidence from relevant RCTs 




III Experiments where subjects are nonrandomly 
assigned to a group 
Case-control or 
cohort study 
IV Comparison groups or observations of groups to 
predict or determine outcomes 
SR of qualitative or 
descriptive studies 
V SR of Gathering data on human behavior or 
describing background on an area of interest 
Qualitative or 
descriptive study 
VI Gathering data on human behavior or describing 
background on an area of interest 
Expert opinion or 
consensus 
VII Opinions of experts or consensus of experts 
Adapted from: Fineout Overhold, E., Melnyk, B., Stillwell, S., & Williamson, K. (2010). 
Critical Appraisal of the Evidence: Part 1. American Journal of Nursing, 110(7) pg. 48. 
Level I. Abbey et al (2015) conducted a systematic review that provided a 
synthesis of evidence that justified the need the further investigating of traumatic related 
events associated to cancer. Zebrack, Kayser, Sundstrom, et al. (2015) addressed cancer 
patients’ emotional and psychosocial needs.  Vodermaier, Linden, and Siu (2009) 
conducted a literature search that yielded 106 validation studies that described a total of 
33 screening measures, particularly newly developed cancer-specific scales, for assessing 
a patient for mental illness. 
Level II. Cordova et al. (2017) focused on the screening options and treatment of 
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cancer-related PTSD by reviewing existing evidence-based approaches for traumatic 
stress. 
Level III. Knaak et al. (2017) revealed that both patient and staff well-being and 
is committed to combating stigma in patient care to promote mental health screenings. 
Level IV. Monson et al, (2008) reported a significant need to screen cancer 
patients for PTSD. Chan et al. (2017) indicated that one third of patients (i.e., 34.1%) 
who were initially diagnosed had persistent or worsening PTSD 4 years later. The authors 
also indicated that there is a need for early identification of this subset of patients who 
have cancer with PTSD to design risk-targeted interventions. 
Level V. Katzman & John (2018), revealed that screening for PTSD in cancer 
patients should be identified and treated appropriately based on age, diagnosis, treatment, 
and by comorbid symptoms. Grassi et al. (2017) examined some of the most significant 
related mental health issues in cancer patients while focusing on recent advances in 
psychosocial and psychopharmacological interventions as a part of a mandatory, 
integrated, and comprehensive approach to psychiatric cancer care. DeSantis et al. (2014) 
reported that it is important for clinicians to understand the unique medical and 
psychosocial needs of cancer survivors and to proactively assess and manage these 
issues. There are a growing number of resources that can assist patients, caregivers, and 
healthcare providers in navigating the various phases of cancer survivorship (DeSantis et 
al., 2014). 
Level VI. Allen et al. (2018) conducted a cohort study that revealed that most 
cancer survivors report negative consequences related to their cancer experience. Allen et 
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al. emphasized that clinicians need the skills to recognize and treat PTSD and other 
psychiatric disorders in this patient population. Caruso et al. (2017) examined some of 
the most significant issues related to screening and the assessments of psychosocial 
morbidity in cancer patients. Gradus et al. (2015) displayed evidence showing an 
association between PTSD diagnoses and various forms of cancer in a nationwide study. 
While French-Rosa, Moye, & Nail (2015) reported that mental health interventions that 
specifically address cancer-related PTSD may improve the cancer patient’s recovery and 
adaptation over time. 
Level VII. Vachon (2006) focused primarily on the psychosocial distress and the 
coping of cancer survivors who have completed their initial treatment and are now 
disease free. Researchers continue to debate the value of such interventions. Staton, 
Rowland, and Ganz (2015) described major psychosocial and physical sequelae facing 
adults during periods of cancer and highlighted the need for PTSD screening. Kimerling, 
Prins, Yeager, and Magruder (2010) recommended using a five-point screening system 
when determining whether the improvement is clinically meaningful using the PCL from 
the DSM-IV for PTSD screening. 
Step 4: Develop Clinical Practice Guideline 
The proposed CPG was: 
1. Cancer patient referral from oncology and/or primary care provider. 
Initial visit scheduled. 
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2. Initial psychiatric evaluation at clinic to include screening of all cancer 
patients regardless of stages/situations with the PHQ9 (i.e., depression 
scale) and the GAD7 (i.e., anxiety scale) 
3. Patient scores above 0 on PHQ9 even though GAD7 is normal: complete 
PHQ9 and GAD7 each visit.  
4. Any abnormal GAD7 results would require PTSD screening with the 
CAPS screening tool. 
5. Patient scores under 4 on PHQ9 and under 3 on the GAD7. Conduct 
yearly PTSD screening with the CAPS screening tool unless there is a 
change in status at subsequent visits. 
6. Initiate guideline per facility protocol for treatment. 
Step 5: Identify an Expert Panel 
The expert panel included three, board-certified, psychiatric nurse practitioners. 
All of the expert panel participants were currently working in the mental health field. All 
panelists evaluated and treated patients with PTSD and had over 10 years of experience 
in this field.  
 Step 6: Obtain Institutional Review Board Approval  
The facility signed the site approval form for the CPG development project.  
Step 7: Obtain Expert Panelists’ Signatures 
Upon Walden Institutional Review Board approval#  09-27-19-0662380, the expert 
panelists signed the form for anonymous questionnaires.  
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Step 8: The Expert Panelists Will Review the Guidelines  
The panelists used the AGREE II instrument and made recommendations for 
revisions. Each panel member reviewed the proposed guidelines using the following 
domains:  
1. Scope and purpose, 
2. Stakeholder involvement, 
3. Rigor of development, 
4. Clarity of presentation, 
5. Applicability, and 
6. Editorial independence (AGREE Research Trust, 2019). 
Step 9: Identify Key Stakeholders and/or End Users 
 I presented the revised guideline to end users, stakeholders, and other experts for 
further discussion on content and usability. 
Step 10: Develop a Final Report 
Step 11: Disseminate Final Report to Key Stakeholders 
Summary 
To address the gap-in-practice at a local psychiatric clinic, I formulated practice-
focused questions regarding the use of PTSD screening tools and a CPG to help identify, 
screen, and treat PTSD patients  from the psychological trauma of cancer. In this project, 
I followed the Walden University DNP Manual for Clinical Practice Guideline 
Development. Through an exhaustive literature search, I identified that the early 
screening for PTSD in cancer patients is needed to improve their quality of life and give 
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them the necessary support to cope with this traumatic event. In the next section, I 
describe the reviews and recommendations made by the expert panel as well as the 
development of the final new practice guideline.  
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Section 4: Findings and Recommendations 
Introduction 
The setting for this DNP project was a private, psychiatric clinic in the north 
central United States providing psychological and psychiatric services to both children 
and adults. This facility has a large influx of cancer patients because it is centrally located 
and has an oncology center. Healthcare providers at this facility are expected to screen 
and manage patients with mental illness using the best evidence-based practices.  
The purpose of this project was to provide healthcare providers with a CPG that 
would promote treatment for PTSD for patients in a variety of cancer situations. 
Developing a CPG addressed the gap in practice at the site and screening this population 
for PTSD will help healthcare providers treat this population with evidence-based 
practices. In Section 4, I describe the findings and recommendations from the expert 
panel development of the new practice guideline. The project questions were: 
1. Based on the current evidence, what is the most appropriate screening tool for 
PTSD in cancer patients?    
2. Based on the evidence reviewed, what CPG recommendations should be made 
to the clinic healthcare providers?  
Findings and Implications  
In order to evaluate the validity of the created guideline, the recommended CPG 
was appraised by an expert panel using the AGREE II tool. The expert panel consisted of 
three psychiatric nurse practitioners working in mental health clinics. All panel members 
had experience treating patients with PTSD. As previously mentioned, the AGREE II tool 
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includes 23 criteria measures to appraise six domains as well as two, overall, global 
rating assessment questions. Each question is rated on 7-point scale with 1 equating to 
strongly disagree and 7 equating to strongly agree. Each domain score is summed by 
totaling the scores of the individual items and dividing by the maximum possible score 
(AGREE II Instrument, 2013). Table 4 describes the results of the expert panel AGREE 
II tool reviews. 
Table 4 
AGREE II Expert Panel Results 







1. The overall 




5 7 7 Improve quality of life 
through accurate 
screening and diagnosis 
for the best evidence-
based practice treatment. 
2.Health questions 
read the guideline 
are specifically 
described. 
5 7 7 Appropriate, based on 
current evidence with 
best patient outcomes. 
3. The population to 
whom the guideline 
is meant to apply is 
specifically 
described. 
6 7 7 Children and adults, 
define ages. 
4. The guideline 
development group 
includes individuals 
from all relevant 
professional groups. 
6 7 7  
5. The views and 
preferences of the 
6 7 7 CAPS is lengthy and may 




have been sought. 
older adolescents and 
adults. Without core 
morbidities and or 
cognitive or intellectual 
disorders. 
6. The target users of 
the guideline are 
clearly defined. 
6 7 7 Adults, defined his age to 
age without 
neurocognitive disorders? 
Ability to accurately 
respond to screening? 
7. Systemic methods 
were used to search 
for evidence. 
6 7 7  




6 7 7  
9. The strength and 
limitations of the 
body of evidence are 
clearly described. 
4 7 7 Strength assist with 
treatment; I know into 
current evidence-based 
practice limitations or 
length of time. Provide 
accurate screening, adapt 
by other professionals. 





5 7 7  
11. The health 
benefits, side effects, 




5 7 7 Risk with screening, no 
risk patient information, 
IRB approved, health 
benefit, yes. 
12. There is an 
explicit link between 
the 
recommendations 
6 7 7 Fix your general 
audience, it may be 
helpful to explain further 





CAPS tool over other 
screening tools. 
13. The guideline 
has been externally 
reviewed by experts 
prior to its 
publications. 
4 7 7 Yes, currently occurring. 
 




5 4 7 Utilizing expert panel 
and clinic. Patient’s been 
screened for feedback. 
Could you provide more 
detail and how you 
would or when you 




are specific and 
unambiguous.  
5 7 7 Yes, however consider 
how this may be different 
with previous history of 
anxiety/depression versus 
new diagnostic 
assessment and new 
onset of symptoms 
during, before, or after 
cancer diagnoses and 
treatment. 
16. The different 
options for 
management of the 
condition or health 




7 Therapy, EMDR, SSRIs, 






4 7 7 Specific to screening, 
yes. 
18. The guideline 
describes facilitators 
and barriers to its 
application. 








19. The guideline 
provides advice 
and/or tools and how 
the 
recommendations 
can be put into 
practice. 
6 6 7 Yes, does the clinic need 
to this weekly? Or allow 
for extra time? 
The CAPS take between 
30 to 60 minutes to 
complete could you 
expand on who would be 
trained to conduct this 
assessment and how it 
would fit in the daily 
workload at the clinic. 







4 7 7 Consider time to 
administer screening, this 
patient has time does the 
provider have time? 




6 7 7 Specific scoring 
provided, more to 
consider to be specific. 
22. The views of the 
funding body have 
not influenced the 
content of the 
guideline. 
7 7 7   
23. Competing 
interests of guideline 
development group 
members have been 
recorded and 
addressed. 
7 7 7  
Overall client 
assessment 
- - - - 
32 
 
1. Rate the overall 
quality of this 
guideline. 
5 6 7  
I would recommend 




Yes Yes There needs to be 
inclusion and exclusion 
criteria including age, 
health literacy/cognitive 
ability and if prior history 
depression anxiety and 
personality disorder are 
influencing factors or if it 
will have different 
screening criteria. Will 




Domain 1  
Domain 1 of the AGREE II tool addressed the scope and purpose of the guideline 
with three questions that focused on guideline objectives and the target population the 
guideline will serve. The overall score for this domain was 91%, which reflects that the 
objectives of the guideline were met. There were no questions or suggestions for 
improvement in this domain from the expert panel. The purpose of the guideline was 
specifically attained and the aim of the guideline, target population, and clinical concerns 
were clearly identified.  
Domain 2 
Domain 2 of the AGREE II tool addressed stakeholder involvement with three 
questions that focused on guideline creation participants, target users of the guideline, 
and whether views and preferences of the target population were taken into consideration. 
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The overall score for this domain was 91%, which reflects stakeholder involvement was 
appropriate.  
Domain 3  
Domain 3 of the AGREE II tool addressed the rigor of development with eight 
questions that focused on the search for evidence and the process used to formulate the 
guideline recommendations. The overall score for this domain was 95%, reflecting that 
the expert panel agreed to develop this guideline. No suggestions were offered in this 
domain.  
Domain 4  
Domain 4 of the AGREE II tool addressed the clarity of presentation with three 
questions that focused on guideline recommendations being specific and identifiable. The 
overall score for this domain was 95%, reflecting a consensus that the guideline 
presentation was easily understood.  
Domain 5  
Domain 5 of the AGREE II tool addressed the applicability of the guideline with 
four questions that focused on barriers to implementing the guideline, guidance for 
integrating it into practice, and the process for monitoring and auditing the guideline in 
the future. The overall score for this domain was 95%, which reflects a consensus from 
the expert panel. There were no suggestions offered. 
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Domain 6  
Domain 6 of the AGREE II tool addressed the editorial independence with two 
questions that focused on the competing interests. The overall score for this domain was 
91%, which was the highest scoring domain. No suggestions were offered. 
Recommendations 
All three experts completed a guideline assessment. The final overall score for the 
quality of the guideline was 92.7% with all experts stating they would recommend the 
guideline. One panelist recommended a modification related to length of provider 
appointments for this screening; however, specific treatments for positive PTSD are not 
necessarily addressed in this CPG because it is used to screen patients for PTSD. Again, 
all expert panels agreed that they would use this guideline as recommended. My 
recommended final CPGs are:  
Step 1: Initial psychiatric evaluation at clinic to include screening of all cancer 
patients regardless of stages/situations with the PHQ9 (i.e., depression scale) 
and the GAD7 (i.e., anxiety scale). 
Step 2: If patient scores above 0 on PHQ9, even though GAD7 is normal, 
complete PHQ9 and GAD7 each visit. 
Step 3: If any abnormal GAD7 results, require PTSD screening with the CAPS 
screening tool. 
Step 4: If patient scores under 4 on PHQ9 and under 3 on the GAD7, conduct 
yearly PTSD screening with the CAPS screening tool unless there is a change in 
status at subsequent visits. 
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Step 5: Initiate the guideline per facility protocol for treatment. All providers 
should to be culturally competent.  
Strengths and Limitations of the Project 
Having a CPG for PTSD screening will ensure that PTSD symptoms do not go 
undiagnosed or treated. With early screening and detection of PTSD, healthcare providers 
I developed this CPG specifically for the project site, so it may not be applicable to other 
sites or specialties. Patients may not be honest when answering screening tools, which 
may impact diagnosis and treatment. This CPG did not specify age recommendations for 
the tool. Children and adolescent patients as well as patients with limited English-
speaking ability might need different screening tools. Prior mental health diagnoses 
would be taken into consideration but not necessarily guide this guideline. Clinicians 
would be completing this guideline with patients. As mentioned by one of the panelists, 




Section 5: Dissemination Plan 
For this scholarly project, I developed a CPG for PTSD screening specific to the 
project site. An expert panel was created to evaluate the guideline. They used the AGREE 
II tool and found it to be appropriate for implementation at the project site. Upon 
receiving their positive evaluation, I presented the guideline to facility administrators. If 
the project site decides to implement the guideline, I will assist with the education of staff 
and implementation of the CPG. Another opportunity to disseminate the information 
would be submitting it to other healthcare systems’ quality improvement teams. This 
would allow the information to be disseminated to other local facilities in the area. A 
final approach would be submitting the project manuscript for publication to an 
appropriate nursing journal, which would broaden the audience to nationwide.  
Scholar  
I experienced personal and professional growth during the process of this project. 
Completing this project allowed me the opportunity to work with a team member, both 
on and off the project site. I learned that it is necessary to conduct an extensive literature 
review to ensure that the most current evidence-based practices and data are reviewed 
before developing a CPG. This experience has also provided me with the knowledge of 
how to create a guideline and evidence of the positive effects it will have on this 
population. As a DNP-prepared scholar, moving forward, I plan to participate in the 




My growth as a practitioner has continued to increase throughout the journey of 
completing my DNP degree. My own morals and values helped shape my desire to learn 
more for my patients and ultimately provide optimal care. This care is based on 
scholarship and research I have completed and the knowledge I have attained along the 
way. My DNP project has helped me align my knowledge and skills with existing 
theoretical frameworks to implement a new CPG and help develop better practices for the 
improvement of patient care. This project has also helped me grow as a leader in nursing.  
Project Manager  
The creation of this guideline allowed me to be a project manager and 
demonstrate my leadership ability as identified by the AACN (2006) DNP Essential II: 
Organizational and Systems Leadership for Quality Improvement and Systems Thinking. 
Walden University provided me with the skills and resources to manage this project from 
start to end. My previous education as well as my personal and professional experiences 
have helped shape and guide me as I completed a successful DNP project that is 
applicable to the clinical setting.  
Summary  
The goal of this project was to identify a gap in nursing practice and develop an 
evidence-based CPG to address it. This guideline could be placed into clinical practice 
and have a positive effect on overall project site patient/resident outcomes and 
readmission rates. The process of earning a DNP provided me with leadership 
experience, confidence, and the knowledge to make a positive impact on patient care 
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while promoting social change. While this is the terminal degree for my educational 
process, I plan to continue my education working toward my PhD. I am so passionate 
about nursing that I want to continue to share my knowledge, experiences, and expertise 
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